The protein product of the c-fes proto-oncogene has been implicated in the normal development of myeloid cells (macrophages and granulocytes). We have previously shown that 151 base pairs of c-fes 5-flanking sequences are sufficient for myeloid cell-specific expression and include functional binding sites for Sp1, PU.1, and a novel nuclear factor (Heydemann, A., Juang, G., Hennessy, K., Parmacek, M. S., and Simon, M. C. (1996) Mol. Cell. Biol. 16, 1676 -1686). This novel hematopoietic transcription factor, termed FEF (c-fes expression factor), binds to a cis-acting element that is located at nucleotides ؊9 to ؊4 of the c-fes promoter between two Ets binding sites (at ؊19 to ؊15 and ؊4 to ؉1) which bind PU.1. We now show that a FEF binding site exists in the myeloid cell-specific regulatory region of a second gene, the ؊2. 
site in both the c-fes promoter and the chicken lysozyme enhancer (CLE), we show that they bind independently. The FEF sites are required for high levels of transcription by both the CLE and the c-fes promoter in transient transfection experiments. Importantly, elimination of the CLE FEF site abolishes all transcriptional activity of this enhancer element. Mutation of the adjacent PU.1 site in either the c-fes promoter or the CLE, reduces activity by approximately 50%. Therefore, transcription of both lysozyme and fes in myeloid cells requires FEF and PU.1. UV cross-linking experiments show that the FEF binding activity consists of a single 70-kDa protein in both human and murine cell lines. FEF binding activity is not affected by antibodies that specifically recognize a number of cloned transcription factors. Collectively, these data indicate that we have identified a novel transcription factor that is functionally important for the expression of at least two myeloid cell-specific genes.
Hematopoiesis is a dynamic developmental process whereby pluripotent hematopoietic stem cells give rise to monocytes, granulocytes, lymphocytes, megakaryocytes, and erythrocytes. Myeloid cells (monocytes/macrophages and granulocytes) are likely derived from a common multipotent precursor cell. As multipotent progenitors undergo monocytic development, they differentiate into monoblasts, promonocytes, monocytes, and finally macrophages. Granulocytic differentiation includes the production of myeloblasts, promyelocytes, myelocytes, and then neutrophils. The factors that regulate these events have not been completely elucidated but include myeloid cell-specific transcription factors, growth factors, growth factor receptors, and signaling molecules such as protein tyrosine kinases. Several mammalian tyrosine kinases exhibit restricted patterns of expression, suggesting that they encode lineage-specific functions (2) (3) (4) . The c-fes proto-oncogene encodes a lineage-restricted, 92-kDa protein tyrosine kinase that includes a Src homology 2 domain and a carboxyl-terminal catalytic domain. c-fes is expressed specifically in myeloid cells (5) (6) (7) (8) (9) and vascular endothelial cells (10) in adult mice and in several rapidly proliferating embryonic tissues (11) .
A requirement for p92 c-fes in macrophage and/or neutrophil development has been suggested by a number of experiments. Introduction of c-fes into K562 cells causes these differentiation resistant cells to produce mature macrophages (12) . Corresponding experiments using antisense oligonucleotides in HL60 cells demonstrate that decreased c-fes expression leads to apoptosis instead of myeloid differentiation upon treatment with the granulocyte inducer, retinoic acid (13, 14) . Furthermore, c-fes tyrosine kinase activity increases following treatment of HL60 cells with differentiation inducers such as Me 2 SO (9, 15) . Recent evidence indicates that c-fes (like c-abl and c-fer) is one of the rare nuclear tyrosine kinases (16) . This specific pattern of expression and its requirement for differentiation and survival strongly suggest a role for p92 c-fes in successful myeloid differentiation.
Despite the apparent importance of p92 c-fes and its limited, myeloid cell-specific expression pattern, very little was known about its transcriptional regulation until recently (1, 17, 18) . These studies have used complementary techniques to produce a functional map of the c-fes promoter. Reporter plasmids driven by the 151-bp 1 human c-fes promoter confer myeloid cell-specific gene expression (1) . The c-fes promoter contains functional binding sites for a number of nuclear regulatory proteins, including Sp1 and Ets transcription factors. Of primary interest are the three 5Ј proximal nuclear protein binding sites shown in Fig. 1 , Ets (Ϫ19 to Ϫ15), FEF (c-fes expression factor) (Ϫ9 to Ϫ4), and Ets (Ϫ4 to ϩ1). Both the upstream and the downstream Ets sites bind PU.1 in myeloid cells, and the * This work was supported by the Howard Hughes Medical Institute (to M. C. S.) and by National Institutes of Health Grant HL52094. The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.
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** To whom correspondence should be addressed: Howard Hughes Medical Institute, University of Chicago, 5841 S. Maryland Ave., MC 1028, Chicago, IL 60637. E-mail: csimon@medicine.bsd.uchicago.edu. site at Ϫ19 is required for maximal transcriptional activity (1, 17) . Gene targeting experiments have shown that PU.1 is essential for the development of macrophages, neutrophils, and T and B cells in mice (19, 20) . PU.1 is also required for the expression of a large number of myeloid lineage-specific genes including: c-fes (1), macrophage colony-stimulating factor receptor (21), CD11b (22) , scavenger receptor (23), Fc␥RIII A (24), Fc␥R1b (25) , and interleukin 1␤ (26) . The Ets family of transcription factors are often found in multiprotein complexes (reviewed in Crepieux et al. (27) ). The list of Ets transcription factor partners is rapidly expanding and currently includes Pip (PU.1 interaction partner)/NF-EM5 (28, 29) , AP-1 family members (30 -33) , and SAP-1 (34) . Of note, the binding of Pip to its recognition element in the immunoglobulin light chain enhancer E 2-4 is dependent on the presence of DNA-bound PU.1 (28) . The partners are often differentially regulated, either spatially or temporally, and the target genes are transcribed only when all factors are present at correct levels. Likewise FEF, which binds to a DNA element 5Ј and immediately adjacent to a PU.1 consensus site, may be important in the combinatorial regulation of lineage-specific genes by PU.1.
In this report, we present data on the binding specificity, function, and biochemical characterization of FEF. We show that FEF, in conjunction with PU.1, is required for the transcription of at least two myeloid cell-specific genes (c-fes and chicken lysozyme) and that the FEF consensus binding site is 5Ј-GAAT(C/G)A-3Ј. The FEF DNA binding site is located immediately adjacent to a 3Ј PU.1 site in both the c-fes and lysozyme genes. FEF, however, can bind to both sites independently of PU.1, unlike the PU.1 cofactor Pip (28, 37) . Remarkably, both a 13-kb human c-fes and a 21.5-kb chicken lysozyme genomic fragment confer myeloid cell-specific expression independent of integration site (35, 36) . FEF may play a role in this process. Furthermore, FEF consists of a single 70-kDa polypeptide that is expressed in hematopoietic cells.
EXPERIMENTAL PROCEDURES
Cell Culture and Nuclear Extracts-The human myeloid cell lines U937 and K562 were maintained in RPMI medium supplemented with 10% fetal bovine serum, penicillin, streptomycin, and glutamine. Mel cells were maintained in Dulbecco's modified Eagle's medium, containing the same additives. The murine adherent macrophage cell line J774.1 was maintained in Dulbecco's modified Eagle's medium containing 20% fetal horse serum, penicillin, streptomycin, glutamine, and nonessential amino acids. For either electroporation or preparation of nuclear extracts, the appropriate cell lines were passaged 1:3 the evening before the procedure was performed. Nuclear extracts were prepared as described previously (38) . Protein concentrations were determined using the Bio-Rad protein assay kit.
Electrophoretic Mobility Shift and UV Cross-linking Assays-Electrophoretic mobility shift analyses (EMSAs) were performed by incubating 10 g of nuclear extract with 10,000 cpm of end-labeled oligonucleotide probe for 30 min at room temperature as described previously (1) . This represents 0.5 ng of probe with a specific activity of 1-2 ϫ 10 7 cpm/g of DNA. Binding buffers contained 7.5 mM Tris-HCl (pH 7.5), 0.74 mM EDTA, 3% Ficoll, 56 mM KCl, and 0.75 mM dithiothreitol, with or without 0.15 ng of bovine serum albumin. Where indicated, 100 ng of cold competitor oligonucleotide or 2 l of specific antibody were included in the room temperature incubation. This constitutes a 200-fold molar excess when the cold competitor extends from Ϫ11 to ϩ11 of c-fes and a 270-fold molar excess when the Ϫ11/ϩ5 oligonucleotide is added. The following antibodies: Creb-1, ATF-2, YY1, Myb, NF-E2, Nrf1, Nrf2, pan-Fos, pan-Jun, PU.1, and Elf-1 specifically concentrated for EMSAs were purchased from Santa Cruz Biotechnology (Santa Cruz, CA). All antibodies have been tested against the specific transcription factor with either nuclear extracts or in vitro transcription/translation reactions (data not shown). The various c-fes probes used for the EMSAs are illustrated in Fig. 1 , and the mutations are illustrated under the appropriate figures. The c-fes probe used for UV cross-linking experiments extends from Ϫ11 to ϩ11 (Fig. 1) and contains labeled dCTP and dGTP and unlabeled bromodeoxy-UTP on the bottom strand. UV cross-linking assays used typical EMSA conditions scaled up five times. The EMSA gel was exposed to 240 mJ of 260-nm ultraviolet light in a Stratalinker (Stratagene) and then exposed to BioMax x-ray film (Eastman Kodak Co.) so that gel-shifted bands could be excised and eluted. Shifted bands were eluted in 1% SDS sample buffer and run on 8% SDS-polyacrylamide gels with molecular weight markers.
Methylation Interference Assays-Methylation interference assays were performed as 5-fold scale-ups of the normal EMSA conditions using methylated probes labeled with [␥-32 P]ATP. Binding reaction mixtures contained 50 g of nuclear extract protein or 5 l of in vitro translated protein and 5 ϫ 10 5 cpm of methylated probe in a final volume of 100 l. Wet gels were exposed to film overnight at 4°C. Piperidine cleavage was performed on eluted DNA from specific shifted and free probe bands. The final 6.66% acrylamide/area gel contained an equal amount of radiation in each lane to facilitate comparisons between free probe and DNA-protein complexes.
Transient Expression Assays-Transient transfections were performed as described previously (1) . The electroporations were performed with 100 g (U937) or 50 g (K562) of luciferase reporter plasmid and 2 g of human growth hormone (GH) reference plasmid. Following electroporation, the U937 cells received 54 nM phorbol 12-myristate 13-acetate to increase transfection efficiency (39) . Cells were harvested 13 h later and assayed for protein content, level of secreted GH, and luciferase activity. Luciferase assays were performed on equivalent amounts of extracted protein. GH activity was measured in the media of transfected cells as specified by the Nichols Institute. As a control for transfection efficiency, luciferase plasmid expression is reported as relative light units normalized to nanograms of GH secreted into the medium. All transfections were performed six or more times to ensure reproducibility of cesium chloride DNA preparations.
The constructs used to analyze the c-fes promoter contained Ϫ446 to ϩ71 of 5Ј sequences relative to the transcription start site (using the numbering assignment of Alcalay et al. (40) ). The PCR-engineered mutations within the c-fes promoter are the underlined letters in the following sequences, starting at bp Ϫ26: mPU.1 upstream, 5Ј-CGGGA-GCACCGGGCGCGGAATCAGGAACTG-3Ј; mFEF, 5Ј-CGGGAGGAG-GAAGCGCGCCACCAGGAACTG-3Ј; and mPU.1 downstream, 5Ј-CGG-GAGGAGGAAGCGCGGAATCACCGGCTG-3Ј. These mutations match those used in the EMSAs to ensure that the specific mutation disrupts the binding of a single protein. The chicken lysozyme enhancer fragment used for these assays extends from Ϫ2694 to Ϫ2535 (41). This fragment was retrieved via PCR and these primers: 5Ј-ttaggatccGTA-CATCTGCAGTTGGCAGAT-3Ј (forward) and 5Ј-ttagtcgacAGATCTGA-TCTCCGCTAACTC-3Ј (reverse). The mutations engineered into the chicken lysozyme enhancer by PCR are the underlined bases in the following sequences starting at bp Ϫ2655: mFEF, 5Ј-GACCACGAGG-AACTA-3Ј and mPU.1, 5Ј-GAGAATGACCGGCTA-3Ј. Once again these mutations are specific for the designated factor based on EMSA analysis. The enhancer was placed into a vector containing either the c-fes or the chicken lysozyme promoter and the luciferase reporter gene. The chicken lysozyme promoter was also retrieved via PCR and the following primers: 5Ј-atagctagcTGCTTCAGATGCTGTTTA-3Ј (forward) and 5Ј-ataaagcttCACACAGCGGGACTGCAA-3Ј (reverse). The final construct extends from Ϫ439 to ϩ14 (42) . All of the transfection constructs have been sequenced to guarantee that the desired mutations were made. This also ensures that no unwanted mutations have been introduced by any of the PCR manipulations.
RESULTS
The Proximal c-fes Promoter Contains a FEF Binding Site and Two PU.1 Binding Sites-The proximal region of the c-fes promoter and the primary transcription initiation site in U937 cells (40) are illustrated in Fig. 1 . We have shown previously that this region is required for high levels of myeloid cellspecific gene expression (1). We identified a functional Ets binding site at Ϫ19 relative to the transcription start site, and showed that PU.1 binds here and transactivates the c-fes promoter in co-transfection assays. We also identified a nuclear protein binding site between Ϫ9 and Ϫ4 (previously called FP4-3Ј) which is required for high levels of expression in myeloid cells. This region includes a nonconsensus AP-1 family member binding site on the opposite strand (5Ј-TGATTCC-3Ј, nucleotides Ϫ10 to Ϫ4). However, we showed that AP-1 family members do not bind to FP4 -3Ј. In the current study, we extend these data and show that the bound protein represents a novel transcription factor. We have therefore labeled the site FEF. Also shown is an immediately adjacent PU.1 binding site at nucleotide Ϫ4 (17) . We wished to assess the role of each of these nuclear protein binding sites in the expression of c-fes and further characterize the FEF DNA-binding activity.
FEF Is Expressed in Murine Hematopoietic
Cells-Although the FEF binding activity was initially identified in the human monoblastic cell line U937, all human cell lines examined also contained an abundant, nonspecific binding activity which nearly co-migrated with the FEF⅐DNA complex in gel retardation assays (1) ( Fig. 2A ). Therefore, we tested the murine macrophage cell line J774.1 for the presence of FEF binding activity hoping to eliminate the nonspecific activity and thus simplify further analyses. As shown in Fig. 2A , both human and murine myeloid cell lines contained FEF binding activity in EMSAs performed with a radiolabeled c-fes oligonucleotide extending from bp Ϫ11 to 5 (lanes 1 and 3). The FEF⅐DNA complex was specifically competed by 100 ng of wild-type cold competitor oligonucleotide (representing a 200-fold molar excess) in assays of both nuclear extracts (lanes 2 and 4). However, as expected, the nonspecific band detected in U937 nuclear extracts was not efficiently competed (open arrow, lanes 1 and 2). In contrast, the J774.1 nuclear extracts did not contain the nonspecific activity (lane 3). Specific PU.1 DNA binding activity was detected in both human and murine myeloid cell lines (arrow). Because none of the tested murine cell lines contained a nonspecific binding activity (see Fig. 2B ), murine cell nuclear extracts were used for the EMSAs throughout this work.
To determine the tissue distribution and cell lineage specificity of the FEF nuclear protein complex, EMSAs were performed with nuclear extracts prepared from murine cell lines and tissues. The human FEF activity is largely restricted to myeloid cell lines, being present in U937, THP-1, HL60, K562, KG-1, and HepG2 cell lines and not present in Jurkat (T cells), Clone13 (B cells), or HeLa (epithelial carcinoma) cell lines (1). However, in murine cell lines the factor is more widely distributed; FEF binding activity was detected in J774.1 (myeloid), Mel (erythroid), RMA (mature T), EL-4 (immature T), 38B9 and 70Z/3 (pre-B), and A20 and WEHI (B) cells (Fig. 2B) . In contrast, FEF was undetectable or expressed at lower levels in the A7R5 smooth muscle cell line (lane 10) or NIH 3T3 fibroblasts (lane 11). PU.1 binding activity was detected in the J774.1, 38B9, 70Z/3, A20, and WEHI cell lines (lanes 1, 5-7, and 8). Based on these experiments, we concluded that the FEF transcription factor is broadly expressed in murine hematopoietic cells.
FEF Binds to the Nucleotide Sequence 5Ј-GAATCA-3Ј-We wished to identify the precise nucleotides required for FEF DNA recognition, therefore EMSAs were performed with various wild-type or mutant oligonucleotides as cold competitors. In a series of preliminary experiments, Mel cell nuclear extracts were incubated with increasing amounts of specific and nonspecific cold competitor oligonucleotides to verify the specificity of FEF binding activity. The wild-type oligonucleotide corresponding to bp -11 to ϩ11 of the c-fes promoter began to compete for FEF binding when 10 ng (a 20-fold molar excess) were added to binding assays while 100 ng (a 150-fold molar excess) of a nonrelated Sp1 oligonucleotide failed to compete (data not shown). Therefore, all experiments were performed using 100 ng of cold competitor oligonucleotides. This represents a 200-fold molar excess of cold competitor over the Ϫ11/ ϩ11 oligonucleotide probe. Fig. 3C shows an EMSA performed and 6) , PU.1 from J774.1 nuclear extracts (lanes 2 and 7) , and J774.1 FEF (lanes 3 and 8) were isolated and analyzed. Methylations of both unbound probe recovered from the native gel and untreated probe are shown for comparison (lanes 4, 5, 9, and 10). Corresponding sequences are displayed for reference. Protein binding sites are bracketed. G residues whose methylation results in a substantial decrease in complex formation include the dotted guanines within the PU.1 site on the upper strand. No other G residues on either strand interfered with FEF or PU.1 complex formation. C, investigation of residues within the FEF binding site, 5Ј-GAATCA-3Ј, critical for protein-DNA complex formation. EMSAs were performed with Mel cell nuclear extracts and radiolabeled Ϫ11/ϩ11 c-fes probe. One hundred nanograms of the indicated unlabeled competing oligonucleotides were added to the binding assays exhibited in lanes 2 through 13. As expected from previous experiments, mutagenesis of the FEF site results in no competition for the FEF complex (lane 4), and an oligonucleotide with mutations in the adjacent PU.1 site still competes (lane 5). A 270-fold molar excess of c-fes oligonucleotides extending from Ϫ11 to ϩ5 with single nucleotide substitutions were used in competition assays shown in lanes 6 -13 . D, EMSA with wild-type and mutant Ϫ11/ϩ11 c-fes oligonucleotide probes. A wild-type oligonucleotide was used in reactions shown in lanes 1-3 and a mutant oligonucleotide with the indicated FEF site changes was used in reactions shown in lanes 4 and 5. with Mel cell extracts and radiolabeled c-fes oligonucleotide (Ϫ11/ϩ11) as the probe. This cell line exhibits specific Elf-1 and FEF binding activities (lanes 1 and 2) . As demonstrated in Fig.  2B , these Mel cells do not contain PU.1 DNA binding activity. However, we detected Elf-1 binding activity at the Ets site based on antibody "supershift" assays (see Fig. 9A ). As shown in lane 4 of Fig. 3C , a 3-bp mutation at positions Ϫ9, Ϫ8, and Ϫ6 of the oligonucleotide inhibits binding of FEF to the cold competitor, thereby identifying at least one of these bases as important for FEF-DNA interaction. The Elf-1 binding activity was not affected as the "mFEF" oligonucleotide still competes for the Elf-1 complex. A mutation at the Ϫ4 Ets site converting 5Ј-GGAA-3Ј to 5Ј-CCGG-3Ј eliminated the ability of the cold
and Ϫ11 had no effect on FEF-DNA recognition (data not shown). We conclude, therefore, that FEF binds at positions Ϫ9 to Ϫ4 within the c-fes promoter which includes the nucleotides 5Ј-GAATCA-3Ј. Importantly, when the Ϫ11/ϩ11 oligonucleotide containing mutations at positions Ϫ9, Ϫ8, and Ϫ6 (mFEF) was used as a probe, FEF binding activity in Mel cell extracts was not detected (Fig. 3D, lanes 4 and 5) .
To identify the guanine residues required for close contact between nuclear DNA-binding proteins and the FEF and PU.1 recognition sites (5Ј-GAATCAGGAA-3Ј) within the fes promoter, methylation interference assays were performed. Methylation interference identifies guanines that when methylated inhibit close interactions between nucleic acids and DNA-binding proteins. As shown in Fig. 3A , the underlined guanine residues on the upper strand in the PU.1 recognition site (5Ј-AGGAA-3Ј) interfered with formation of the PU.1⅐DNA complex in J774.1 nuclear extracts when methylated (lane 1 versus lanes 4 and 5). These results are in agreement with methylation interference analysis of the PU.1 complex reported for the immunoglobulin light-chain enhancer E 2-4 (43). In contrast, no methylated guanine residues in the FEF site interfered with this DNA complex. Furthermore, no guanine residues on the opposite strand of either the FEF or the PU.1 site displayed sites of close contact (Fig. 3B) . To overcome the limitation that methylation interference assays demonstrate close contacts only between guanines and proteins, single site mutations were made throughout the sequence 5Ј-CGGAATCA-3Ј in the c-fes Ϫ11/ϩ5 oligonucleotide. These mutant oligonucleotides were used as cold competitors in EMSAs with Mel cell nuclear extracts because Mel cells do not contain the PU.1 complex (Fig.  3C) . If either the adenine at position Ϫ7, thymidine at Ϫ6, or the cytosine at Ϫ5 are mutated, the Ϫ11/ϩ5 c-fes oligonucleotide failed to compete (Fig. 3C, lanes 10 -12) . This experiment clearly reveals that the core nucleotide sequence required for FEF binding is ATC (lanes 10 -12) within the 5Ј-GAATCA-3Ј site. The additional residues within the FEF site are also important for FEF binding, but more than 1 bp needs to be mutated to inhibit FEF binding (lane 4). To verify the requirement for one of these single base pairs, the oligonucleotide mutated at the thymidine residue was labeled and used as a probe in EMSAs. As expected, this probe did not produce a FEF-shifted complex (data not shown). Lane 13 of Fig. 3C further delineates the extent of the FEF binding site. In this lane the A to T mutation partially inhibits FEF binding to the cold competitor. We therefore conclude that the core base pairs of the FEF binding site are ATC at positions Ϫ7 to Ϫ5 of the c-fes promoter.
PU.1 Is Not Required for FEF-DNA Interaction-PU.1 and
Pip bind to adjacent sites within the E 2-4 enhancer, and the binding of Pip is dependent on the presence of DNA-bound PU.1 in lymphoid cells (28) . EMSAs were performed with J774.1 nuclear extracts which contain PU.1 binding activity (unlike Mel nuclear extracts). As shown in Fig. 4 (1) . We have also shown that a mutation in the FEF site of the c-fes promoter decreases luciferase activity by 80% in U937 cells (1) . However, we wished to compare the functional importance of the Ϫ19 PU.1 and FEF sites in the c-fes promoter with the downstream PU.1 site (Ϫ4 to ϩ1) having shown that nuclear proteins bind FIG. 4 . EMSA using J774.1 nuclear extracts and a wild-type c-fes oligonucleotide probe extending from nucleotides ؊11 to ؉5 or the same oligonucleotide with a mutation at the ؊4 PU.1 binding site. Where indicated, unlabeled competing oligonucleotides or 2 l of antibodies that specifically react with the murine PU.1 or Elf-1 proteins were added to the binding reactions.
to all three sites. Transient transfections were performed with the wild-type c-fes promoter (Ϫ446 to ϩ71), or promoters mutated at the Ϫ19 PU.1 site, Ϫ9 FEF site or the Ϫ4 PU.1 site. These mutations were chosen based on binding specificities revealed by EMSAs, and each mutation specifically inhibits PU.1 or FEF complex formation (Fig. 4) (1) . The data presented in Fig. 5 clearly demonstrate that all three nuclear protein binding sites are required for high levels of c-fes activity in myeloid cells. Mutagenesis of the upstream PU.1 site resulted in an 83% loss of activity in U937 cells (Fig. 5A ) and a 78% loss in K562 cells (Fig. 5B) . The FEF site mutation caused a 62% reduction in activity in U937 cells. In contrast, the 19% reduction caused by a FEF site mutation in K562 cells was not statistically significant. Mutagenesis of the downstream PU.1 site resulted in a decrease in promoter activity in myeloid cells: 53 and 68% in U937 and K562 cells, respectively. We concluded that all three sites play a functional role in the expression of the c-fes promoter in myeloid cells, although FEF may be more important for c-fes expression in monoblastic U937 cells than in multipotent K562 cells (see "Discussion").
The Chicken Lysozyme Enhancer Also Contains a FEF Binding Site-Upon identification of the FEF site within the c-fes promoter, DNA data base searches were conducted which might reveal potential FEF binding sites in other genes. The nucleotides extending from Ϫ11 to ϩ5 of the c-fes promoter (Fig. 1) were used in such computer analyses. This sequence includes the functional FEF site and the Ets site located at position Ϫ4. One homologous sequence identified in this search is located within the Ϫ2.7-kb enhancer of the chicken lysozyme gene (41) . The chicken lysozyme gene has been extensively studied as a model of myeloid differentiation and tissue-specific gene expression (36, 41) . Furthermore, the lysozyme Ϫ2.7-kb enhancer element has been shown to be an important regulator of chicken lysozyme expression in myeloid cell transient transfection assays (41) . Interestingly, both DNA elements contain neighboring FEF and PU.1 sites in the same orientation (see Fig. 6A ). To determine if FEF can bind to the lysozyme element, EMSAs were performed using oligonucleotides derived from the CLE (nucleotides Ϫ2655 to Ϫ2634) and J774.1 extracts. Both wild-type and mutant oligonucleotides were tested. Fig.  6B demonstrates that FEF and PU.1 binding activities were detected using a CLE oligonucleotide as the probe (lane 6). These complexes were competed by both the wild-type CLE oligonucleotide (lane 7) and the c-fes Ϫ11/ϩ11 oligonucleotide (lane 8). Furthermore, a wild-type CLE oligonucleotide competes for FEF and PU.1 binding to the c-fes Ϫ11/ϩ11 oligonucleotide (data not shown). In addition, mutations within the CLE for the FEF and PU.1 sites were tested in competition EMSAs. The FEF mutation (5Ј-GAATGA-3Ј to 5Ј-CCACGA-3Ј) and the PU.1 mutation (5Ј-AGGAA-3Ј to 5Ј-ACCGG-3Ј) within CLE oligonucleotides are the same as those engineered in c-fes. These oligonucleotides behaved the same as c-fes oligonucleotides in competition experiments with the c-fes Ϫ11/ϩ11 probe (Fig. 6B, lanes 2 to 5) : the CLE mFEF DNA failed to compete FEF and the CLE mPU.1 failed to compete PU.1. As further proof that the CLE oligonucleotide binds to FEF, a cell distribution EMSA was performed and the expression pattern was identical to that shown for c-fes in Fig. 2B (data not shown) . Only those cells which bound the FEF site of the c-fes oligonucleotide also bound the FEF site of the CLE. These data demonstrate that the chicken lysozyme enhancer also contains a FEF binding site adjacent and 5Ј to a PU.1 site.
The FEF and PU.1 Sites Are Functional in the Chicken Lysozyme Enhancer-Transient transfection assays were conducted to analyze the functional significance of the FEF and PU.1 sites of the chicken lysozyme enhancer (Fig. 7) . The EMSAs of Fig. 6B indicate that the mutations utilized in EMSAs and transient transfection assays are specific for independent binding of either FEF or PU.1. That is, the FEF mutated oligonucleotide still binds to PU.1 (Fig. 6B, lane 4) , and the PU.1-mutated oligonucleotide still binds FEF (Fig. 6B,  lane 5) . The activity of the chicken lysozyme enhancer was measured in conjunction with the chicken lysozyme promoter in two different myeloid cell lines. The data presented in Fig. 7   FIG. 5. Functional analysis of the  PU.1 and FEF sites in human myeloid  cells. A, the 446-bp c-fes promoter with mutations in the Ϫ19 PU.1 site, the FEF site, or the Ϫ4 PU.1 site was electroporated onto U937 cells. Luciferase activity for the wild-type c-fes promoter was set at 100%. B, the same four plasmids were introduced into K562 cells.
were obtained from transient transfection assays using U937 (A) and K562 (B) cells. Inclusion of a wild-type CLE, nucleotides Ϫ2694 to Ϫ2535, increased the average luciferase activity of the chicken lysozyme promoter 10 -25-fold (Fig. 7, A and B) . Of note, mutation of the FEF site completely eliminated enhancer activity in both cell lines examined. Mutation of the PU.1 site also decreased enhancer activity by approximately 45% in U937 cells and 35% in K562 cells. Moreover, similar results were obtained when the CLE was assayed in conjunction with the c-fes promoter (data not shown). We therefore conclude that the PU.1 binding site is required for maximal activity of the chicken lysozyme enhancer and that the FEF site is essential for enhancer function.
The FEF Complex Consists of a Single 70-kDa Protein-To characterize the number and size of polypeptide(s) required for FEF DNA binding activity, UV cross-linking experiments were conducted. Binding assays were performed with J774.1 nuclear extracts, the Ϫ11/ϩ5 bromodexoyurdidine-labeled probe, and ultraviolet light. Appropriate bands were eluted and then run on a denaturing polyacrylamide gel. Fig. 8A (lane 2) demonstrates that the principle protein detected in the FEF⅐DNA complex migrates as a 70-kDa protein. Additional faint bands were detected, which we believe are proteolytic products (see below). For comparison, cross-linked Elf-1 eluted from the same EMSA and migrating as a 90-kDa protein and PU.1 migrating as a 30-kDa protein are also shown (lanes 1 and 3) . Importantly, we show that no labeled polypeptides obtained from the FEF complex correspond to the sizes predicted for Elf-1, PU.1 or their proteolytic products. These data are consistent with antibody data, which show that the FEF complex does not contain Elf-1 or PU.1 (Fig. 4, lanes 4 and 5) .
UV cross-linking analyses were extended to other cell lines previously shown to contain FEF binding activity by gel shift assays (Fig. 2B) (1) . In the three murine hematopoietic cell lines (Mel, EL-4, and J774.1) and three human lines (U937, HL60, and HepG2) examined, FEF migrates as a 70-kDa protein (Fig. 8B) . Once again the proteolytic products do not correspond to the 30-kDa PU.1 polypeptide. Importantly, the labeled proteins present at the bottom of the figure probably represent proteolytic products of the FEF protein that remain labeled due to their proximity to the DNA during the UV-crosslinking step. They are present in substoichiometric amounts and vary from cell line to cell line. For example, two smaller species of approximately 25-30-kDa in J774.1 macrophages react with the radioactive bromodeoxyuridine oligonucleotide. However, Mel erythroblasts and EL-4 T cells contain very low levels of the 25-kDa polypeptide, although all three cell lines contain FEF DNA binding activity. The most likely explanation for these results is that the FEF transcription factor consists of a single protein and that the smaller radiolabeled polypeptides represent truncated FEF generated by proteolysis during the cross-linking procedure. In summary, we consistently detect a 70-kDa monomer in all of the cell lines assayed by UV crosslinking. Therefore, we believe that the FEF binding activity consists of a single 70-kDa protein in murine and human hematopoietic cells.
FEF Appears to Be a Novel Transcription Factor-The FEF site was initially identified in experiments analyzing the potential of AP-1 family members to bind nucleotides at Ϫ10 to Ϫ4 of the c-fes promoter (1). The reasons that AP-1 family members were investigated are 1) the opposite strand (5Ј-TGATTCC-3Ј; Fig. 1 ) is similar to the published AP-1 consensus site (5Ј-TGATGTC-3Ј); and 2) there are many examples of AP-1 family members binding to DNA elements adjacent to Ets binding sites (31, 44, 45) . Utilization of various mutated cold competitor oligonucleotides allowed the identification of a complex that interacts with the putative AP-1 site (Fig. 3C) . However, Fig. 9A demonstrates that this complex is not due to AP-1 family members because antibodies specific for Fos, Jun, and related proteins do not affect the band in J774.1 (lanes 6 and 7) or Mel nuclear extracts (lanes 13 and 14) . This antibody experiment has been repeated using human U937 extracts with the same results (data not shown). Both antibodies shift an AP-1 complex generated with U937 nuclear extracts and an AP-1 oligonucleotide from the metalothionine promoter (data not shown). Furthermore, AP-1 consensus oligonucleotides from the metalothionine and collagenase promoters did not compete for the FEF⅐DNA complex using nuclear extracts from Mel, J774, or U937 cells (data not shown). This accumulated data convinced us that AP-1 family members do not bind to this region of the c-fes promoter. FIG. 6 . A, nucleotide sequence of the c-fes promoter from Ϫ11 to ϩ5 and the chicken lysozyme enhancer from Ϫ2965 to Ϫ2958 upstream of the transcription start site, including binding sites for FEF and PU.1. B, EMSA performed with a radiolabeled c-fes or CLE (nucleotides Ϫ2956 to Ϫ2958) oligonucleotide used as a probe. Indicated competing oligonucleotides were added to the assays shown in lanes 2 to 5, 7, and 8. Arrows, Elf-1, FEF, and PU.1 complexes.
To determine if the FEF complex included other known transcription factors, EMSAs were performed with additional antibodies. The candidate transcription factors were chosen because 1) their expression pattern overlaps with cells containing FEF (Fig. 2B) , 2) the size of the known protein is close to 70-kDa (Fig. 8), and 3) the binding site appears similar to that shown for FEF. The putative factors which were tested include Elf-1, PU.1 Myb, Fos, Jun, CREB (p43), ATF-2 (p70), and YYI (p65). None of these antibodies affected the FEF complex detected in Mel cell extracts (Fig. 9, A and B) , nor in extracts prepared from J774.1 (Fig. 9A ) or U937 cells (data not shown). Because ATF-2 is also 70 kDa and its consensus binding sequence (5Ј-TGACGTCA-3Ј) is somewhat similar to the FEF site (5Ј-GAATCA-3Ј), 6 g of ATF-2 protein (Santa Cruz Biotechnologies) were included in a gel shift reaction. However, this protein did not produce a shifted complex with the radiolabeled c-fes oligonucleotide probe (data not shown). Furthermore, if ATF-2 is bound to a consensus ATF-2 oligonucleotide, the ATF-2 antibody reacts with this complex (data not shown). Collectively, these data eliminate the ATF-2 transcription factor as the FEF DNA-binding protein.
NF-E2 is a transcription factor that binds to an extended AP-1 site, 5Ј-(T/C)TGCTGA(C/G)TCA(T/C)-3Ј (46) . This sequence matches 9 of 12 nucleotides on the opposite strand of the c-fes FEF binding site (see Fig. 1 ). However, NF-E2 binds DNA as a heterodimer of p18 and p45 subunits (46, 47) , and UV cross-linking experiments clearly indicate that FEF consists of a single 70-kDa protein. Furthermore, the p45 subunit of NF-E2 is not present in the murine macrophage cell line J774.1 (47) , which abundantly expresses FEF (see Fig. 8, A, lane 2,  and B, lane 3) . Therefore, FEF represents a distinct DNA binding activity from the NF-E2 complex. Other transcription factors can be eliminated as candidates for FEF by expression pattern. For example, although Nrf2 is 66 kDa and binds to an extended AP-1 site, its mRNA is abundant in HeLa cells (48) , which had undetectable amounts of FEF by EMSA (1). Similarly, Nrf1, which is 65 kDa and also binds to an extended AP-1 site, can be eliminated as a candidate for FEF because it is expressed in HeLa cells (49) . Of note, antibodies specific for the p45 subunit of NF-E2, Nrf1, and Nrf2 failed to recognize the FEF⅐DNA complex in J774.1 or Mel nuclear extracts (data not shown). Therefore, we believe that FEF is a novel hematopoietic transcription factor. DISCUSSION 
Several lines of evidence indicate that p92
c-fes is critical for the differentiation and survival of cells that constitute the myeloid lineages (monocytes/macrophages and neutrophils (12) (13) (14) . For example, increased levels of kinase activity correlate with the maturation of macrophages and neutrophils, and inhibition of c-fes protein synthesis leads to apoptosis during neutrophilic differentiation (9, (13) (14) (15) . Furthermore, the expression of c-fes is severely limited in adult mammals to myeloid cells, myeloid precursors, and vascular endothelial cells (5) (6) (7) (8) (9) (10) . In an effort to identify nuclear factors responsible for the tight transcriptional regulation of this unusual protein tyrosine kinase, we have characterized functional binding sites for proteins critical to expression of the c-fes promoter in transient transfection assays. Given the importance of c-fes in myeloid development, we reasoned that such factors should also be critical for macrophage and neutrophil production. To date, the factors important for c-fes regulation include Sp1, PU.1, and a novel hematopoietic factor termed FEF.
FEF specifically binds to the DNA element 5Ј-GAATCA-3Ј. This element appears to be distinct from recognition elements published for all other cloned transcription factors. FEF binding activity was initially identified in human myeloid cell lines (1) . However, to simplify further analysis of this factor, murine cells have now been employed. We have shown that FEF is broadly expressed throughout murine hematopoietic lineages and is found in macrophages, erythroblasts, and T and B cells. (lanes 3, 4, 10,  and 11) . B, Mel cell extracts were assayed by additional antibodies including those specific for Creb-1, ATF-2, and YY1. None of the antibodies tested reacted with the FEF ⅐DNA gel shift complex. appears to be preferentially expressed in hematopoietic cells in mouse and man.
A second FEF binding site has now been identified in the Ϫ2.7-kb enhancer of the chicken lysozyme gene. Chicken lysozyme has been extensively studied as a model for myeloid cell-specific gene expression. Lysozyme is selectively activated in late stages of macrophage differentiation (50, 51) . Remarkably, both the 13-kb human c-fes locus and the 21.5-kb chicken lysozyme gene are expressed in transgenic mice independent of the integration site and proportional to the transgene copy number (35, 36) . Furthermore, both transgenes function as independent regulatory units that are specific to myeloid cells. It is intriguing that both of these transcription units include functional binding sites for FEF immediately adjacent and 5Ј to functional PU.1-binding sites. FEF and PU.1 are critical for maximal expression of the c-fes promoter and the lysozyme enhancer in transient transfection experiments. In fact, disruption of the FEF site in the lysozyme enhancer completely eliminates all enhancer activity provided by this 155 bp DNA element in the context of two myeloid cell lines. FEF may be more important for c-fes expression in more differentiated myeloid cells: a FEF mutation has a bigger effect on c-fes promoter activity in monoblastic U937 cells than myeloid precursor K562 cells. This does not seem to be the case for lysozyme, where a FEF site mutation severely effects expression in both cell lines. The differences for FEF requirement in the expression of fes and lysozyme likely depends on the context of this site in the two genes.
Although both the PU.1 and FEF sites play a functional role in the expression of c-fes and lysozyme, the two factors appear to bind in an independent manner. FEF DNA-binding activity is detected in erythroid and T lymphoid cells which lack PU.1. Furthermore, FEF-DNA interactions can be observed using radiolabeled probes where the PU.1 site has been eliminated. This is in marked contrast with the nuclear factor Pip/NF-EM5 which also binds to PU.1-adjacent sites within the immunoglobulin light chain enhancers E 3Ј , E 2-4 , and E 3-1 (29, 43) . Although PU.1 binds DNA as a single factor, the binding of Pip is dependent on the presence of DNA-bound PU.1 that is phosphorylated on serine residue 148 (28, 52) . The possibility remains that FEF and PU.1 can physically interact, but that this interaction is not stable enough for detection as ternary FEF⅐PU.1⅐DNA complexes during mobility shift analyses.
FEF DNA binding activity appears to consist of a single 70-kDa polypeptide, based on UV cross-linking experiments. Furthermore, the same 70-kDa species is present in all murine and human hematopoietic cell lines examined. Other radiolabeled polypeptides exhibiting faster electrophoretic mobilities are present in the UV cross-linking assays. However, they are present in substoichiometric amounts and likely represent truncated FEF polypeptides. Determination of the apparent molecular weight of FEF has allowed us to exclude a number of known transcription factors on the basis of size. Other factors can be excluded on the basis of expression pattern, DNA recognition element, or immunoreactivity to antibodies specific for each factor. We have carefully documented that FEF is distinct from other myeloid transcription factors such as Myb or CEBP/␣ in addition to PU.1, Elf-1, AP-1, ATF-2, Creb-1, or YY1. Critical bases for protein-DNA interaction within the FEF recognition site 5Ј-GAATCA-3Ј are ATC. However, the chicken lysozyme enhancer FEF site consists of the nucleotides 5Ј-GAATgA-3Ј indicating that a preliminary FEF consensus site for DNA recognition is 5Ј-GAAT(C/G)A-3Ј. We conclude that FEF represents a novel hematopoietic transcription factor that specifically binds to a unique DNA element functionally important for at least two myeloid cell-restricted genes, c-fes and lysozyme. Efforts to expression clone the 70-kDa FEF protein based on DNA binding are underway. Further characterization of this novel transcription factor will be useful for the analysis of myeloid cell-specific gene expression and the first myeloid cell locus control elements.
